Yahoo Finance

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Perrigo, founded in 1887, is a leading manufacturer of generic over-the-counter healthcare products and supplier of infant formulas for the store-brand market. Perrigo's private-label consumer products encompass a variety of cold/allergy, gastrointestinal, first aid, motion sickness, vitamin, smoking cessation, and other remedies. The company has a market cap of approximately $4 billion after divesting its RX pharmaceutical business in 2021. Headquartered in Dublin, Ireland, Perrigo has over 9,100 employees. The shares are a component of the S&P 400 Mid-Cap Index.